Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This clinical trial is designed to compare the pharmacokinetic characteristics of combination and separate administration of Crestor(Rosuvastatin) and Micardis(Telmisartan). Also investigate drug interaction between separate and combination administration.
Total number of subjects is 48. 4 group(12 for 1 group), 2 period, consecutive 6 day administration, 16 days washout after 6th day of administration.
The subjects of Part 1 take Crestor alone and Crestor+Micardis combination by a cross-over design during 2 each period.
The other subjects of Part 2 take Micardis alone and Crestor+Micardis combination by a cross-over design during 2 each period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | This arm is consist of 12 subject. Crestor 20mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2. |
|
| 2 | Experimental | This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Crestor 20mg alone for 6 day during period 2. |
|
| 3 | Experimental | This arm is consist of 12 subject. Micardis 80mg alone for 6 day during period 1. Crestor 20mg and Micardis 80mg for 6 day during period 2. |
|
| 4 | Experimental | This arm is consist of 12 subject. Crestor 20mg and Micardis 80mg for 6 day during period 1. Micardis 80mg alone for 6 day during period 2. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) | Drug | For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period. For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period. |
| Measure | Description | Time Frame |
|---|---|---|
| AUC | AUC Ī,ss of Rosuvastatin and Telmisartan | 72hr |
| Cmax | Cmax,ss of Rosuvastatin and Telmisartan | 72hr |
| Measure | Description | Time Frame |
|---|---|---|
| AUC | AUC last,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan | 72hr |
| AUC | AUC inf,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1.History of and clinically significant disease 2.Sitting blood pressure meeting the following criteria at screening: 150 ⤠systolic blood pressure â¤90 (mmHg) and 95 ⤠diastolic blood pressure ⤠50 (mmHg) amd 100 ⤠Heart rate ⤠40 3. A history of drug abuse or the presence of positive reactions to drugs that have abuse potential in urine screenings for drugs.
4. Administration of other investigational products within 90 days prior to the first dosing.
5. Administration of herbal medicine within 30 days or administration of ethical drugs within 14 days or administration of over-the-counter (OTC) drugs within 7 days prior to the first dosing of the investigational product (if the investigator (study doctor) determines that the person meets other criteria appropriately, the relevant person may participate in the study).
6.Have AST(SGOT) or/and ALT(SGPT) > 3 times of normal upper limit at the time of screening 7. Volunteers considered not eligible for the clinical trial by the investigator (study doctor) due to reasons including laboratory test results, ECGs, or vital signs.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Severance Hospital, Yonsei University | Seoul | 120-752 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24998012 | Derived | Son M, Kim Y, Lee D, Roh H, Son H, Guk J, Jang SB, Nam SY, Park K. Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study. Clin Ther. 2014 Aug 1;36(8):1147-58. doi: 10.1016/j.clinthera.2014.06.007. Epub 2014 Jul 3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 72hr |
| Tmax | Tmax,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan | 72hr |
| t1/2 | t1/2 of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan | 72hr |
| Cmin | Cmin,ss of Rosuvastatin, N-desmetyl Rosuvastatin and Telmisartan | 72hr |
| AUC | AUCĪ,ss of N-desmetyl Rosuvastatin | 72hr |
| Cmax | Cmax,ss of N-desmetyl Rosuvastatin | 72hr |
| ID | Term |
|---|---|
| D000068718 | Rosuvastatin Calcium |
| D000077333 | Telmisartan |
| ID | Term |
|---|---|
| D013449 | Sulfonamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D005464 | Fluorobenzenes |
| D006845 | Hydrocarbons, Fluorinated |
| D006846 | Hydrocarbons, Halogenated |
| D006838 | Hydrocarbons |
| D013450 | Sulfones |
| D013457 | Sulfur Compounds |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided